Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines
Ru(quin)<sub>2</sub> emerges as a potent candidate for BC treatment, with multiple mechanisms of action involving apoptosis, autophagy, and cell cycle arrest. Further studies are warranted to elucidate its detailed molecular mechanisms and evaluate its therapeutic potential in vivo, moving toward clinical applications for both ER-positive and triple-negative BC management.
Authors
- Salah A. Sheweita (ORCID: https://orcid.org/0000-0001-8113-4403)
- Alessio Nencioni (ORCID: https://orcid.org/0000-0001-5068-8884)
- Asmaa Namatalla
- Ahmed Sultan (ORCID: https://orcid.org/0000-0001-5776-1837)
- A. Khalifa (ORCID: https://orcid.org/0000-0002-2131-5496)
- Mohamed A. Khalifa
Institutions
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Ospedale Policlinico San Martino (IT)
- King Khalid University (SA)
- University of Genoa (IT)
- Alexandria University (EG)
Publication Details
- Journal
- Cancers
- Published
- 2025-01-09
- DOI
- https://doi.org/10.3390/cancers17020195
- Citations
- 3
- Primary Topic
- Metal complexes synthesis and properties
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- U.S. Department of Defense
- California Breast Cancer Research Program
- Associazione Italiana per la Ricerca sul Cancro